Yazar "Maral, Senem" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Co-occurence of follicular lymphoma and Langerhans cell histiocytosis with primary parotid gland involvement: a case report
    (Elsevier Editora Ltda, 2021) Albayrak, Aynur; Yıldız, Abdulkerim; Albayrak, Murat; Uçaryılmaz Özhamam, Esra; Maral, Senem
    Follicular lymphoma (FL) is one of the most common types ofNon-Hodgkin Lymphoma (NHL) which originates from B-cells.1Generally it has an indolent clinical course, althoughhistological transformation to aggressive lymphoma mayoccur in 25-35 % of cases, and therafter the prognosis hasbeen reported to be poor. Transformation to histiocytic sar-coma may also be seen but very rarely
  • [ X ]
    Öğe
    The Charlson Comorbidity Index Predicts Poor Prognosis in Elderly AML Patients
    (AKAD DOKTORLAR YAYINEVI, 2023) Tığlıoğlu, Mesut; Albayrak, Murat; Tığlıoğlu, Pınar; Yıldız, Abdulkerim; Doğan, Servihan; Afacan Öztürk, Hacer Berna; Maral, Senem; Sağlam, Buğra; Aras, Merih Reis; Dilek, İmdat
    Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults and patients older than 65 years have a poor prognosis. Patient-related factors, such as comorbid conditions that affect performance status, and insufficient organ functions, explain why elderly patients have a worse prognosis. The Charlson Comorbidity Index (CCI), is used to predict prognosis according to comorbidities. This retrospective study was conducted on patients diagnosed with AML between 2010 and 2019. Patients >60 years were included. Demographic information, comorbidities, CCI, ECOG ( Eastern Cooperative Oncology Group) score, cytogenetic characteristics, treatment regimens, treatment response, follow-up periods were recorded for all patients. Evaluation was made of a total of 82 patients with a mean age of 71.18 ± 7.67. The median follow-up was 6.7 months. The median number of comorbidities was 1 [0.0-4.0] with the median CCI score of 3 [2.0-6.0]. Median overall survival (OS) was 7.0 months [3.1-10.8] and PFS was 6.8 months [3.6-10.0]. As the median CCI score was 3, patients were divided into two groups as CCI > 3 and CCI ? 3. Age, gender, ECOG, cytogenetic risk profile, first-line treatment and CR1 achievement status were all similar in both groups (p > 0.05). Patients with CCI > 3 had significantly shorter OS than patients with CCI ? 3 (3.6 months [0.3-29.3] vs 8.6 months [0.2-60.2], p= 0.049). The results of the current study demonstrated that CCI, can be used as a prognostic index in elderly patients with AML independently of other patient and disease-related characteristics.